These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
673 related articles for article (PubMed ID: 32387812)
1. Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer. Lin YT; Tsai TH; Wu SG; Liu YN; Yu CJ; Shih JY Lung Cancer; 2020 Jul; 145():1-9. PubMed ID: 32387812 [TBL] [Abstract][Full Text] [Related]
2. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709 [TBL] [Abstract][Full Text] [Related]
3. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation. Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion. Nokihara H; Ogino H; Mitsuhashi A; Kondo K; Ogawa E; Ozaki R; Yabuki Y; Yoneda H; Otsuka K; Nishioka Y BMC Cancer; 2022 Jun; 22(1):597. PubMed ID: 35650550 [TBL] [Abstract][Full Text] [Related]
5. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC. Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475 [TBL] [Abstract][Full Text] [Related]
6. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754 [TBL] [Abstract][Full Text] [Related]
7. Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation. Wang S; Yan B; Zhang Y; Xu J; Qiao R; Dong Y; Zhang B; Zhao Y; Zhang L; Qian J; Lu J; Zhao R; Han B Int J Cancer; 2019 Jun; 144(11):2880-2886. PubMed ID: 30474188 [TBL] [Abstract][Full Text] [Related]
8. Real-world data on treatment outcomes in Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036 [TBL] [Abstract][Full Text] [Related]
9. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation. Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281 [TBL] [Abstract][Full Text] [Related]
10. Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment. Tseng JS; Yang TY; Chen KC; Hsu KH; Huang YH; Su KY; Yu SL; Chang GC Cancer Res Treat; 2018 Oct; 50(4):1164-1174. PubMed ID: 29228521 [TBL] [Abstract][Full Text] [Related]
11. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Soo RA; Han JY; Dafni U; Cho BC; Yeo CM; Nadal E; Carcereny E; de Castro J; Sala MA; Bernabé R; Coate L; Provencio Pulla M; Garcia Campelo R; Cuffe S; Hashemi SMS; Früh M; Massuti B; Garcia-Sanchez J; Dómine M; Majem M; Sanchez-Torres JM; Britschgi C; Pless M; Dimopoulou G; Roschitzki-Voser H; Ruepp B; Rosell R; Stahel RA; Peters S; Ann Oncol; 2022 Feb; 33(2):181-192. PubMed ID: 34839016 [TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status. Liao J; Huang Y; Gan J; Pang L; Ali WAS; Yang Y; Chen L; Zhang L; Fang W Cancer Control; 2022; 29():10732748221081360. PubMed ID: 35201951 [TBL] [Abstract][Full Text] [Related]
13. Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI. Chiang CL; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH Target Oncol; 2020 Aug; 15(4):503-512. PubMed ID: 32696212 [TBL] [Abstract][Full Text] [Related]
14. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial. Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885 [TBL] [Abstract][Full Text] [Related]
16. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450 [TBL] [Abstract][Full Text] [Related]
17. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610 [TBL] [Abstract][Full Text] [Related]
18. Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. Li W; Qiu T; Guo L; Ling Y; Gao Y; Ying J; He J Cancer Lett; 2018 Jun; 423():9-15. PubMed ID: 29524556 [TBL] [Abstract][Full Text] [Related]
19. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931 [TBL] [Abstract][Full Text] [Related]
20. Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib. Kuo CS; Huang CH; Liu CY; Pavlidis S; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT Target Oncol; 2019 Aug; 14(4):433-440. PubMed ID: 31346928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]